Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,206.80
(
-1.14%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.62
(
-1.08%
)
Bitcoin
81,170.51
(
0.86%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Protector

Send PM Follow Ignore
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Protector

Re: itsabouttime post# 267482

Thursday, 06/30/2016 12:14:54 PM

Thursday, June 30, 2016 12:14:54 PM

Post# of 347009
itsabouttime, incorrect companies!

Planned studies include bavituximab in combination with pembrolizumab (AZN) in hepatocellular carcinoma,and durvalumab (MERCK) in NSCLC. Good



pembrolizumab is from MERCK and durvalumab from AZN. You switched them.

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote